Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 24.0% | 33.2% | (48.5%) | 59.1% | 51.9% | 49.3% | 45.8% | 42.9% | 31.4% | 28.7% | 87.5% | 103.7% | 70.1% | 23.3% | 26.0% | 24.3% | 0.4% | 31.6% | 21.6% | 25.5% |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Microsoft Corp's last 12-month Return on Equity (ROE) is 0.6%, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Return on Equity (ROE) for Gilead Sciences, Inc. have been 19.0% over the past three years, and 17.5% over the past five years.
As of today, Gilead Sciences, Inc.'s Return on Equity (ROE) is 0.6%, which is lower than industry median of 18.5%. It indicates that Gilead Sciences, Inc.'s Return on Equity (ROE) is Bad.